Portal de Periódicos da CAPES

A Randomized Trial of Methotrexate in Combination With Infliximab for the Treatment of Crohn's Disease

2008; Elsevier BV; Volume: 135; Issue: 1 Linguagem: Inglês

10.1053/j.gastro.2008.05.061

1528-0012

Brian Feagan, John WD McDonald, Remo Panaccione, Robert Enns, Çharles N. Bernstein, Terry Ponich, Raymond Bourdages, Donald MacIntosh, Chrystian Dallaire, Albert Cohen, Richard Fedorak, Pierre Paré, Alain Bitton, Fred Saibil, Frank Anderson, Allan Donner, Cindy J. Wong, Guangyong Zou, Margaret K. Vandervoort, Marybeth Hopkins, Gordon R. Greenberg,

Acute Lymphoblastic Leukemia research

Both methotrexate (MTX) and infliximab (IFX) are effective therapies for active Crohn's disease (CD); however, it is unknown whether the combination is superior to IFX alone. Methods: We conducted a 50-week, double-blind, multicenter, controlled trial that compared combination therapy to IFX alone in patients with active CD. Eligible patients had initiated prednisone induction therapy within 6 weeks. Patients previously treated with IFX and those at risk for MTX or IFX toxicity were excluded. Patients were randomly assigned to receive MTX 25 mg subcutaneously weekly or placebo (PBO).